These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37264710)

  • 1. A Dual-Targeting Liposome Enhances Triple-Negative Breast Cancer Chemoimmunotherapy through Inducing Immunogenic Cell Death and Inhibiting STAT3 Activation.
    Luo K; Yang L; Yan C; Zhao Y; Li Q; Liu X; Xie L; Sun Q; Li X
    Small; 2023 Oct; 19(40):e2302834. PubMed ID: 37264710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
    Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
    Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer.
    Luo K; Gao Y; Yin S; Yao Y; Yu H; Wang G; Li J
    Acta Biomater; 2021 Oct; 134():649-663. PubMed ID: 34289420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Celecoxib Augments Paclitaxel-Induced Immunogenic Cell Death in Triple-Negative Breast Cancer.
    Qian X; Yang H; Ye Z; Gao B; Qian Z; Ding Y; Mao Z; Du Y; Wang W
    ACS Nano; 2024 Jun; 18(24):15864-15877. PubMed ID: 38829727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanocarrier-mediated immunogenic chemotherapy for triple negative breast cancer.
    Liu Y; Qiu N; Shen L; Liu Q; Zhang J; Cheng YY; Lee KH; Huang L
    J Control Release; 2020 Jul; 323():431-441. PubMed ID: 32360890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Codelivery of Shikonin and siTGF-β for enhanced triple negative breast cancer chemo-immunotherapy.
    Li J; Zhao M; Liang W; Wu S; Wang Z; Wang D
    J Control Release; 2022 Feb; 342():308-320. PubMed ID: 35031387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression.
    Kim M; Lee JS; Kim W; Lee JH; Jun BH; Kim KS; Kim DE
    J Control Release; 2022 Aug; 348():893-910. PubMed ID: 35760233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel/sunitinib-loaded micelles promote an antitumor response in vitro through synergistic immunogenic cell death for triple-negative breast cancer.
    Qin T; Xu X; Zhang Z; Li J; You X; Guo H; Sun H; Liu M; Dai Z; Zhu H
    Nanotechnology; 2020 Sep; 31(36):365101. PubMed ID: 32434167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-targeting liposomes with active recognition of GLUT
    Pu Y; Zhang H; Peng Y; Fu Q; Yue Q; Zhao Y; Guo L; Wu Y
    Eur J Med Chem; 2019 Dec; 183():111720. PubMed ID: 31553933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer.
    Qiu X; Qu Y; Guo B; Zheng H; Meng F; Zhong Z
    J Control Release; 2022 Jan; 341():498-510. PubMed ID: 34883139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing TNBC Chemo-immunotherapy via combination reprogramming tumor immune microenvironment with Immunogenic Cell Death.
    Wu S; Liu D; Li W; Song B; Chen C; Chen D; Hu H
    Int J Pharm; 2021 Apr; 598():120333. PubMed ID: 33540008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
    Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
    Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting CD73 with flavonoids inhibits cancer stem cells and increases lymphocyte infiltration in a triple-negative breast cancer mouse model.
    Mediratta K; El-Sahli S; Marotel M; Awan MZ; Kirkby M; Salkini A; Kurdieh R; Abdisalam S; Shrestha A; Di Censo C; Sulaiman A; McGarry S; Lavoie JR; Liu Z; Lee SH; Li X; Sciumè G; D'Costa VM; Ardolino M; Wang L
    Front Immunol; 2024; 15():1366197. PubMed ID: 38601156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages.
    Chen M; Miao Y; Qian K; Zhou X; Guo L; Qiu Y; Wang R; Gan Y; Zhang X
    Nano Lett; 2021 Jul; 21(14):6031-6041. PubMed ID: 34240603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A marine-derived small molecule induces immunogenic cell death against triple-negative breast cancer through ER stress-CHOP pathway.
    Wen H; Zhong Y; Yin Y; Qin K; Yang L; Li D; Yu W; Yang C; Deng Z; Hong K
    Int J Biol Sci; 2022; 18(7):2898-2913. PubMed ID: 35541893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling.
    Liu H; Yan R; Xiao Z; Huang X; Yao J; Liu J; An G; Ge Y
    Breast Cancer Res; 2023 Apr; 25(1):43. PubMed ID: 37069669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulator-Mediated Suppressive Tumor Immune Microenvironment Remodeling Nanoplatform for Enhanced Immuno/Chemo/Photothermal Combination Therapy of Triple Negative Breast Cancer.
    Wang A; Yang X; Li R; Shao L; Zhao W; Hu X; Fang K; Chai K; Shi S; Dong C
    ACS Appl Mater Interfaces; 2023 Nov; 15(46):53318-53332. PubMed ID: 37943829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.